Two units (250 mL) of ABO-compatible CP were transfused at 3 (IQR 2-7) days from admission in addition to cancer‐directed treatment and COVID-19–specific therapies (hydroxychloroquine, azithromycin, remdesivir, and tocilizumab). This evidence concerns the gene CP and COVID-19.